HS-20093, a fully humanized IgG1 antibody-drug conjugate targeting B7-H3, is being evaluated in combination with HRS-5041, a PROTAC targeting androgen receptors, for the treatment of advanced prostate cancer. The market for prostate cancer therapeutics is significant, with increasing demand for innovative treatments, particularly for metastatic castration-resistant prostate cancer (mCRPC). The combination approach may provide a competitive edge against existing therapies by targeting multiple pathways involved in tumor progression. Given the current landscape, successful outcomes could position Hansoh BioMedical favorably in the oncology market, potentially leading to partnerships or licensing opportunities. Diligence should focus on the safety profile and efficacy data as they emerge, particularly in relation to existing therapies targeting similar pathways.